A phase-II study of atezolizumab in combination with obinutuzumab or rituximab for relapsed or refractory mantle cell or marginal zone lymphoma or Waldenström's macroglobulinemia.

Adult Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols / adverse effects Humans Lymphoma, B-Cell, Marginal Zone / drug therapy Rituximab / therapeutic use Waldenstrom Macroglobulinemia / drug therapy
Atezolizumab Waldenström’s macroglobulinemia lymphoma obinutuzumab rituximab

Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 21 1 2022
medline: 26 5 2022
entrez: 20 1 2022
Statut: ppublish

Résumé

We report efficacy, safety and biomarker data from a phase-II study evaluating atezolizumab (eight 21-day cycle as induction therapy) in combination with obinutuzumab in patients with relapsed/refractory mantle cell lymphoma (MCL,

Identifiants

DOI: 10.1080/10428194.2021.2015765 PMID: 35045765
pubmed: 35045765
doi: 10.1080/10428194.2021.2015765
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
Rituximab 4F4X42SYQ6
atezolizumab 52CMI0WC3Y
obinutuzumab O43472U9X8

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1058-1069

Auteurs

Panayiotis Panayiotidis (P)

Laikon General Hospital and National and Kapodistrian University of Athens, Athens, Greece.

Gayane Tumyan (G)

N.N. Blokhin Russian Cancer Research Centre, Moscow, Russian Federation.

Catherine Thieblemont (C)

AP-HP, Hôpital Saint-Louis, and Université de Paris, Paris, France.

Vadim V Ptushkin (VV)

City Clinical Hospital Named After S.P. Botkin, Moscow, Russian Federation.

Ana Marin-Niebla (A)

Hospital Universitari Vall d'Hebron, Barcelona, Spain.

Ramon García-Sanz (R)

Hospital Universitario de Salamanca (HUSA/IBSAL/CIBERONC), Salamanca, Spain.

Steven Le Gouill (S)

Service d'Hématologie Clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France.

Anastasios Stathis (A)

Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland, and Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.

Alessia Bottos (A)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Habib Hamidi (H)

Genentech, Inc, South San Francisco, CA, USA.

Pablo Katz (P)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Thomas Perretti (T)

F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Jenna C Willis (JC)

Roche Products Ltd, Welwyn Garden City, UK.

Christian Buske (C)

CCC Ulm, Institute of Experimental Cancer Research, University Hospital Ulm, Ulm, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › A phase-II study of atezolizumab in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › A phase-II study of atezolizumab in...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › A phase-II study of atezolizumab in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A phase-II study of atezolizumab in...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Syndromes lymphoprolifératifs › Lymphomes › Lymphome malin non hodgkinien › Lymphome B › Lymphome B de la zone marginale › A phase-II study of atezolizumab in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux d'origine murine › Rituximab › A phase-II study of atezolizumab in...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Macroglobulinémie de Waldenström › A phase-II study of atezolizumab in...